ALBT Stock - Avalon GloboCare Corp.
Unlock GoAI Insights for ALBT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.33M | $1.26M | $1.20M | $1.39M | $1.38M |
| Gross Profit | $267,829 | $238,188 | $272,728 | $414,518 | $390,203 |
| Gross Margin | 20.1% | 19.0% | 22.7% | 29.8% | 28.3% |
| Operating Income | $-4,927,732 | $-15,753,683 | $-8,792,895 | $-8,833,830 | $-12,454,019 |
| Net Income | $-7,903,394 | $-16,707,010 | $-11,930,847 | $-9,090,499 | $-12,679,438 |
| Net Margin | -592.7% | -1330.5% | -992.4% | -653.5% | -920.3% |
| EPS | $-8.44 | $-1.59 | $-1.36 | $-1.09 | $-1.61 |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Visit WebsiteEarnings History & Surprises
ALBTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $-0.06 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-2.02 | — | — |
Q2 2025 | May 13, 2025 | — | $-1.43 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-1.99 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-1.82 | — | — |
Q3 2024 | Aug 19, 2024 | — | $-2.85 | — | — |
Q2 2024 | May 30, 2024 | — | $-1.80 | — | — |
Q2 2024 | Apr 15, 2024 | — | $-13.49 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-2.10 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-3.75 | — | — |
Q2 2023 | May 22, 2023 | — | $-4.20 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-0.30 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-9.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.29 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.23 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.27 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.24 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.28 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.28 | — | — |
Latest News
ALBT stock has given up its prior gain. Avalon GloboCare shares were trading higher after the company announced the acquisition of generative AI software company RPM Interactive in a $19.5M all-stock transaction.
➖ NeutralAvalon GloboCare shares are trading higher after the company announced the acquisition of generative AI software company RPM Interactive in a $19.5M all-stock transaction.
📈 PositiveEXCLUSIVE: Avalon GloboCare Says Now Believes Stockholders' Equity Exceeds $2.5M Minimum Nasdaq Requirement As A Result Of Acquisition
📈 PositiveEXCLUSIVE: Avalon GloboCare Acquires Generative AI Software Company, RPM Interactive, In $19.5M All-Stock Transaction; Avalon Issued 19,500 Shares Of Series E Non-Voting Convertible Preferred Stock
📈 PositiveFrequently Asked Questions about ALBT
What is ALBT's current stock price?
What is the analyst price target for ALBT?
What sector is Avalon GloboCare Corp. in?
What is ALBT's market cap?
Does ALBT pay dividends?
Similar Stocks
Real Estate SectorExplore stocks similar to ALBT for comparison